Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer

Medical Oncology

Volumn 26, Issue 2, 2009, Pages 210-214

  Coronel, Jaime ^a   Cetina, Lucely ^a   Candelaria, Myrna ^a   González Fierro, Aurora ^a   Arias, Daimy ^a   Cantu, David ^a   Dueñas González, Alfonso ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cervical cancer; Chemotherapy resistant; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IMATINIB; MESYLIC ACID; ONDANSETRON; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MEDIASTINUM; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 67651031402     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9108-5     Document Type: Article

References (16)

1. Parkin DM, Bray F, Ferlay J. Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2000;55:74-108.
2. Candelaria M, Cetina L, de la Garza J, Dueñas-González A. Clinical implications of gemcitabine in the treatment of cervical cancer. Eur J Cancer Suppl. 2007;5:37-43. doi: 10.1016/S1359-6349(07)70014-9. (Pubitemid 46754969)
3. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419-34. doi: 10.1007/s11912-005-0007-z.
4. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-9. doi: 10.1200/JCO.2004.04.170. (Pubitemid 41103724)
5. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Gynecologic oncology group study: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol. 2005;23:4626-33. doi: 10.1200/JCO.2005.10. 021. (Pubitemid 46224065)
6. Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH, et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic oncology group (GOG) study [Abstract]. J Clin Oncol. 2008;26:LBA5504.
7. LB Wenzel H Huang D Cella BJ Monk MW Sill SD McMeekin DE Cohn LM Ramondetta CH Boardman J Benda 2008 Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: a Gynecologic oncology group (GOG) study [abstract] J Clin Oncol 26 5529
8. DT Rein CM Kurbacher 2001 Kurbacher CM: The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects Anticancer Drugs 12 787 795 10.1097/00001813-200111000-00001 11707645 10.1097/00001813-200111000-00001 1:CAS:528:DC%2BD38XjtVCmsQ%3D%3D (Pubitemid 33151526)
9. P Boabang CM Kurbacher H Kohlhagen A Waida 2000 Amo-Takyi BK: Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-tumor chemosensitivity assay Anticancer Drugs 11 843 848 10.1097/00001813-200011000-00008 11142692 10.1097/00001813-200011000-00008 1:CAS:528:DC%2BD3cXptFSqs7o%3D
10. JV Fiorica 2002 Update on the treatment of cervical and uterine carcinoma: focus on topotecan Oncologist 7 Suppl 5 36 45 10.1634/theoncologist 12324632 10.1634/theoncologist.7-suppl-5-36 1:CAS:528:DC%2BD38Xos1Whs7s%3D 7-suppl-5-36
11. DK Armstrong 2004 Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity Oncologist 9 33 42 10.1634/theoncologist 14755013 10.1634/theoncologist.9-1-33 1:CAS:528: DC%2BD2cXhs1Smt7k%3D 9-1-33
12. K Noda H Sasaki K Yamamoto T Yamamoto R Nishimura T Sugiyama 1996 Phase II trial of topotecan for cervical cancer of the uterus [Abstract] J Clin Oncol 15 754
13. A Bookman JA Blessing P Hanjani TJ Herzog 2000 Andersen WA: Topotecan in squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group Gynecol Oncol 77 446 449 10.1006/gyno.2000.5807 10831357 10.1006/gyno.2000.5807 1:CAS:528:DC%2BD3cXjs1WgtLg%3D (Pubitemid 30368565)
14. NR Abu-Rustum S Lee 2000 Massad LS: Topotecan for recurrent cervical cancer after platinum-based therapy Int J Gynecol Cancer 10 285 288 10.1046/j.1525-1438.2000.010004285.x 11240688 10.1046/j.1525-1438.2000. 010004285.x
15. P Hoskins E Eisenhauer S Beare M Roy P Drouin G Stuart P Bryson R Grimshaw V Capstick 1998 Zee B: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study J Clin Oncol 16 2233 2237 9626225 1:STN:280:DyaK1c3ovFCltw%3D%3D
16. PG Rose NH Gordon N Fusco L Fluellen M Rodríguez ST Ingalls 2000 Hoppel CL: A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma Gynecol Oncol 78 228 234 10.1006/gyno.2000.5844 10926808 10.1006/gyno.2000.5844 1:CAS:528:DC%2BD3cXltlCjtb4%3D (Pubitemid 30650359)